CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Set to Begin Enrolling Brain Cancer Drug Trial Participants
Brain cancer drug developer CNS Pharmaceuticals is finalizing preparations to begin March enrollment of patients in its potentially pivotal Phase 2 trial evaluating its promising lead candidate, Berubicin, for the overall survival improvement of glioblastoma (“GBM”) patients Glioblastomas are a type of brain cancer that have continued to elude effective therapy over the past century … Continue reading “CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Set to Begin Enrolling Brain Cancer Drug Trial Participants”